We conducted a high-risk redo mitral valve replacement through a right mini-thoracotomy without rib spreading (redo-MICS MVR) under systemic hyperkalemia combined with circulatory arrest to circumvent complications associated with cardioplegia delivery. The patient, a 75-year-old man, had a predicted mortality rate of 20%. Initial antegrade cardioplegia successfully induced cardiac arrest, which was administered every 30 min. However, upon infusion of the second dose of cardioplegia, the aortic root pressure was approximately 20 mmHg. Despite multiple attempts to re-cross the clamp, the aortic root pressure did not improve. Consequently, retrograde cardioplegia was considered, but due to significant adhesion of the inferior vena cava, this approach was abandoned. Thus, the procedure was altered to utilize systemic hyperkalemia without aortic cross-clamping (ACC). Given the preoperative transesophageal echocardiography (TEE) diagnosis of mild aortic regurgitation, maintaining a clear surgical field was challenging, necessitating the combination of redo-MVR with circulatory arrest. This case exemplifies the successful management of cardioplegia delivery complications using systemic hyperkalemia and circulatory arrest, resulting in a favorable postoperative recovery for the patient.

Download full-text PDF

Source
http://dx.doi.org/10.1051/ject/2024027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661784PMC

Publication Analysis

Top Keywords

systemic hyperkalemia
16
circulatory arrest
16
cardioplegia delivery
12
delivery complications
8
combined circulatory
8
aortic root
8
root pressure
8
cardioplegia
6
arrest
5
technique avoiding
4

Similar Publications

We conducted a high-risk redo mitral valve replacement through a right mini-thoracotomy without rib spreading (redo-MICS MVR) under systemic hyperkalemia combined with circulatory arrest to circumvent complications associated with cardioplegia delivery. The patient, a 75-year-old man, had a predicted mortality rate of 20%. Initial antegrade cardioplegia successfully induced cardiac arrest, which was administered every 30 min.

View Article and Find Full Text PDF

COL4A2-Related Disorder Presenting in Adulthood With Rhabdomyolysis.

Am J Med Genet A

December 2024

Department of Clinical Genomics, Mayo Clinic, Scottsdale, Arizona, USA.

The alpha 1 and 2 chains of type IV collagen, encoded by the COL4A1 (MIM 120130) and COL4A2 (MIM 120090) respectively, play essential roles in the vascular basement membranes. Pathogenic variants in COL4A1/ COL4A2 are associated with autosomal dominant cerebral angiopathies. The clinical manifestations of COL4A1/COL4A2-related disorders include: aneurysms, intracerebral hemorrhage, polymicrogyria, porencephaly, heterotopia, periventricular leukomalacia, epilepsy, and neurodevelopmental disorders.

View Article and Find Full Text PDF

Mitochondrial disorders are often underrecognized as potential causes of rhabdomyolysis, a condition characterized by acute muscle breakdown that can lead to local and potentially systemic complications, with the possibility of being life-threatening. Accounts of rhabdomyolysis as a peri-operative complication associated with mitochondrial disorders are rare; therefore, this study is noteworthy. We describe a case of rhabdomyolysis that occurred during the peri-operative period in a middle-aged male with Charcot-Marie-Tooth (CMT) disease-like peripheral neuropathy.

View Article and Find Full Text PDF
Article Synopsis
  • Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin condition that causes blisters and other complications, and this study tested the safety of losartan, a medication that may slow its progression.
  • The study was a phase 1/2 trial involving children aged 2-16 with confirmed RDEB, focusing on identifying any serious side effects of losartan over a treatment period of 10 months.
  • Primary safety concerns monitored included severe drops in blood pressure, allergic reactions, and changes in potassium levels, along with evaluating the drug's effectiveness through various clinical scores.
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the costs associated with adverse events (AEs) in untreated patients with advanced renal cell carcinoma (aRCC) in the USA, analyzing a large dataset from 2014 to 2021.
  • The research involved 1,681 patients and found that a significant majority experienced at least one AE, leading to increased medical costs; expenses for these AEs varied widely, from under $300 to nearly $60,000.
  • The study highlights limitations of observational data but emphasizes the financial impact of AEs on the treatment of aRCC, especially those costing over $10,000 within 30 days of diagnosis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!